# Filing Detail

Form 8-K - Current report:
SEC Accession No. 0001558370-21-012078
Filing Date
2021-08-26
Accepted
2021-08-26 07:16:45
Documents
21
Period of Report
2021-08-24
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 3.02: Unregistered Sales of Equity Securities
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | 8-K | plx-20210824x8k.htm iXBRL | 8-K | 53666
2 | EX-4.1 | plx-20210824xex4d1.htm | EX-4.1 | 100287
3 | EX-4.2 | plx-20210824xex4d2.htm | EX-4.2 | 1525863
4 | EX-4.3 | plx-20210824xex4d3.htm | EX-4.3 | 84650
5 | EX-10.1 | plx-20210824xex10d1.htm | EX-10.1 | 403762
6 | EX-10.2 | plx-20210824xex10d2.htm | EX-10.2 | 42916
7 | EX-99.1 | plx-20210824xex99d1.htm | EX-99.1 | 16830
8 | GRAPHIC | plx-20210824xex4d2001.jpg | GRAPHIC | 3085
9 | GRAPHIC | plx-20210824xex4d2002.jpg | GRAPHIC | 2628
10 | GRAPHIC | plx-20210824xex99d1001.jpg | GRAPHIC | 11384
| Complete submission text file | 0001558370-21-012078.txt |  | 2707245

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
11 | EX-101.SCH | plx-20210824.xsd | EX-101.SCH | 3195
12 | EX-101.LAB | plx-20210824_lab.xml | EX-101.LAB | 16162
13 | EX-101.PRE | plx-20210824_pre.xml | EX-101.PRE | 10907
14 | EXTRACTED XBRL INSTANCE DOCUMENT | plx-20210824x8k_htm.xml | XML | 4870

Mailing Address 2 UNIVERSITY PLAZA SUITE 100 HACKENSACK NJ 07601
Business Address 2 UNIVERSITY PLAZA SUITE 100 HACKENSACK NJ 07601 201-696-9345
Protalix BioTherapeutics, Inc. (Filer) CIK: 0001006281 (see all company filings)

EIN.: 650643773 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33357 | Film No.: 211208817
SIC: 2836 Biological Products, (No Diagnostic Substances)